La cadena de opciones muestra datos clave de las opciones de acciones de Viridian Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Viridian Therapeutics..

Viridian Therapeutics (NASDAQ:VRDN) Bolsa, Cadena de Opciones

VIRIDIAN THERAPEUTICS INC

Viridian Therapeutics

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics Inc

<a href="https://www.nytimes.com/2025/06/03/health/multiple-myeloma-car-t-immunotherapy.html" title="https://www.nytimes.com/2025/06/03/health/multiple-myeloma-car-t-immunotherapy.html">https://www.nytimes.com/2025/06/03/health/multiple-myeloma-car-t-immunotherapy.html</a>

News

Rumors

Trading Ideas

LEGN

Watching Legend Biotech; Traders Circulate NY Times Article Titled "From No Hope to a Potential Cure for a Deadly Blood Cancer", Users Compare The Co's CAR-T Therapy, CARVYKTI, Saying It Offers Hope Of Cure

ChargePoint Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is about to plug into the earnings grid, and Wall Street's biggest brains are already circling the EV charging play. The company reports <a href="https://www.benzinga.com/quote/CHPT/earnings">first quarter results</a> after the bell Wednesday, with expectations for a loss of 5 cents per share on $108.07 million in revenue.
But here's the twist: the stock is quietly mounting a comeback.
After shedding over 54% in the past year, ChargePoint has sprinted +33% over the last month, sparking serious interest from hedge fund royalty. Steve Cohen's Point72, Cliff Asness' AQR and Philippe Laffont's Coatue Management have all initiated new positions as of March, buying the dip at an average of around $0.84 &#8211; which is where the stock was trading on Wednesday.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45547600/whats-going-on-with-chargepoint-stock-today-3">What&#8217;s Going On With ChargePoint Stock On Wednesday?</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0604"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04062354/Screenshot-2025-06-04-at-3.53.37-PM.png" alt="" class="wp-image-937991" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04062354/Screenshot-2025-06-04-at-3.53.37-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04062354/Screenshot-2025-06-04-at-3.53.37-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0604">Chart created Benzinga Pro</a>
Technically, CHPT stock is sending all the right short-term signals. The stock trades above its eight, 20, and 50-day simple moving averages (SMA), with the MACD (moving average convergence/divergence) indicator in positive territory and the RSI (relative strength index) climbing to 63.17, suggesting bullish momentum without yet entering the overbought territory.
Still, it's not all green lights. The longer-term 200-day average sits way up at $1.04, keeping some caution in play. But short-term traders are clearly charging up: the eight-day SMA bullish signal, rising volume, and sentiment reversal have made this penny EV stock a hot pre-earnings momentum play.
And when names like Cohen, Asness, and Laffont start nibbling at a company once left for dead — you know something's up.
Tonight's earnings could either recharge the rally or blow a fuse. For now, the big money is plugged in, and the CHPT stock chart is blinking bullish.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45164220/evgo-vs-chargepoint-tariffs-technicals-and-the-road-to-profitability">EVgo Vs. ChargePoint: Tariffs, Technicals, And The Road To Profitability</a></li>
</ul>
Photo: YuniqueB/Shutterstock

Hedge Funds

Technicals

Previews

Markets

Tech

CHPT

Cohen, Asness, Laffont Bet On ChargePoint - Will Q1 Earnings Spark A Breakout?

Macro Economic Events

Econ #s

Economics

USA Gasoline Inventories 5.219M Barrel Build Vs 1.500M Barrel Build Est.; 2.441M Barrel Draw Prior

USA EIA Weekly Distillates Stocks 4.230M Barrel Build Vs 2.200M Barrel Build Est.; 0.724M Barrel Draw Prior

Macro Notification

General

USA Crude Oil Inventories 4.304M Barrel Draw Vs 2.900M Barrel Draw Est.; 2.795M Barrel Draw Prior

Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) has outperformed the market over the past 20 years by 1.64% on an annualized basis producing an average annual return of 9.97%. Currently, Crown Holdings has a market capitalization of $11.42 billion. 
Buying $1000 In CCK: If an investor had bought $1000 of CCK stock 20 years ago, it would be worth $6,677.67 today based on a price of $98.09 for CCK at the time of writing.
<h3>Crown Holdings's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749047412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Crown Holdings 20 Years Ago Would Be Worth This Much Today

Agreement involves Natural Graphite Material; complements existing 2024 agreement covering Synthetic Anode Active Materials
Follows Graphite One's listing on U.S. Federal Fast-41 Permitting Dashboard and completion of its NI 43-101 compliant Feasibility Study funded by a $37.3 million Department of Defense award under the Defense Production Act
Graphite One CEO, Anthony Huston: "This Agreement makes Graphite One the only company to date to provide both natural and synthetic graphite materials required for battery anodes to a U.S. EV company."
VANCOUVER, BC, June 4, 2025 /PRNewswire/ - Graphite One Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/GPH#TSXV">GPH</a>)&nbsp;(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GPHOF#OTCQX">GPHOF</a>) ("Graphite One", or the "Company"), is pleased to announce that as part of its plan to build a complete U.S. supply chain for advanced graphite materials, the Company has entered into a second non-binding supply agreement (the "Supply Agreement") for anode active materials ("AAM") with Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) ("Lucid"), maker of the world's most advanced electric vehicles.

Contracts

GPHOF

LCID

TSXV:GPH

Graphite One Signs Second Supply Agreement With Lucid Group For Natural Graphite Anode Materials; Deal Follows Completion Of $37.3M DOD-Funded Feasibility Study And Fast-41 Permitting Milestone

UBS analyst Joshua Spector maintains Tronox Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) with a Buy and lowers the price target from $10 to $8.5.

Price Target

Analyst Ratings

TROX

UBS Maintains Buy on Tronox Holdings, Lowers Price Target to $8.5

UBS analyst Michael Lasser maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Neutral and lowers the price target from $54 to $48.

UBS Maintains Neutral on Academy Sports, Lowers Price Target to $48

UBS analyst Rodrigo Alcantara maintains BBB Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBB#NYSE">TBBB</a>) with a Neutral and raises the price target from $32 to $33.

TBBB

UBS Maintains Neutral on BBB Foods, Raises Price Target to $33

WIIM

GTLS

Chart Industries shares are trading lower after the company announced a $19 billion merger with Flowserve.

UBS analyst Mauricio Serna maintains Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) with a Buy and raises the price target from $84 to $95.

UBS Maintains Buy on Signet Jewelers, Raises Price Target to $95

<a href="https://www.bloomberg.com/news/articles/2025-06-04/us-said-to-refuse-air-cover-for-europe-forces-in-postwar-ukraine?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-04/us-said-to-refuse-air-cover-for-europe-forces-in-postwar-ukraine?embedded-checkout=true</a>

'US Said to Refuse Air Cover for Europe Forces in Postwar Ukraine'- Bloomberg

PTON

Peloton shares are trading higher. On Tuesday, a report suggested the company is launching a resale market for used bikes and treadmills.

HealthEquity shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and raised its FY26 guidance. Also, multiple firms raised their respective price targets on the stock.

During UBS Conference Ford CFO Reportedly Says 100% Of Steel And Aluminium Is Produced In U.S.; Tariffs Impacts Related To Steel Would Be Small

RBC Capital analyst Michael Siperco upgrades Novagold Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NG#AMEX">NG</a>) from Sector Perform to Outperform and raises the price target from $5 to $7.

Upgrades

RBC Capital Upgrades Novagold Resources to Outperform, Raises Price Target to $7

Oppenheimer analyst Owen Lau maintains CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) with a Outperform and raises the price target from $282 to $300.

Oppenheimer Maintains Outperform on CME Group, Raises Price Target to $300

TTGT

TTGT stock has given up its prior gain. TechTarget shares were trading higher. The company reported FY24 financial results.

Oppenheimer analyst Scott Schneeberger maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Outperform and raises the price target from $189 to $235.

FERG

Oppenheimer Maintains Outperform on Ferguson Enterprises, Raises Price Target to $235

Press Releases

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

Comments

Viridian Therapeutics

Viridian Therapeutics (VRDN) Opciones

Viridian Therapeutics (NASDAQ:VRDN) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL